Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
addendum, advertising, age, artificial, beneficial, beta, blocked, cartridge, chapter, chemotherapy, concept, configuration, decree, delay, delaying, dirucotide, dissolved, divested, Effient, endpoint, enroll, enrolling, factor, formal, innovation, Jackson, key, literature, mature, misuse, movement, Novapharm, opposed, outlicensing, placebo, progressed, progression, progressive, Ralph, release, released, resubmitted, secondary, sector, small, solanezumab, SPE, statistically, stent, stimulate, study, subcutaneously, subsidize, thrombotic, transparency, week
Filing tables
Filing exhibits
Related press release
LLY similar filings
Filing view
External links
| EXHIBIT 32. | Section 1350 Certification |
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Eli Lilly and Company, an Indiana corporation (the “Company”), does hereby certify that, to the best of their knowledge:
The Quarterly Report on Form 10-Q for the quarter ended June 30, 2009 (the “Form 10-Q”) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date July 31, 2009 | s/ John C. Lechleiter | |||
| John C. Lechleiter, Ph.D. | ||||
| Chairman, President, and Chief Executive Officer | ||||
| Date July 31, 2009 | s/ Derica W. Rice | |||
| Derica W. Rice | ||||
| Senior Vice President and Chief Financial Officer | ||||